CN101896190A - 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤 - Google Patents

用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤 Download PDF

Info

Publication number
CN101896190A
CN101896190A CN2008801206945A CN200880120694A CN101896190A CN 101896190 A CN101896190 A CN 101896190A CN 2008801206945 A CN2008801206945 A CN 2008801206945A CN 200880120694 A CN200880120694 A CN 200880120694A CN 101896190 A CN101896190 A CN 101896190A
Authority
CN
China
Prior art keywords
administered
day
melanoma
days
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801206945A
Other languages
English (en)
Chinese (zh)
Inventor
伊斯雷尔·里奥斯
辛西娅·W·塔特希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of CN101896190A publication Critical patent/CN101896190A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2008801206945A 2007-12-12 2008-12-08 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤 Pending CN101896190A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310107P 2007-12-12 2007-12-12
US61/013,101 2007-12-12
PCT/US2008/013480 WO2009075813A1 (en) 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)

Publications (1)

Publication Number Publication Date
CN101896190A true CN101896190A (zh) 2010-11-24

Family

ID=40755783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801206945A Pending CN101896190A (zh) 2007-12-12 2008-12-08 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤

Country Status (8)

Country Link
US (1) US20100330093A1 (https=)
EP (1) EP2240195A4 (https=)
JP (1) JP2011506436A (https=)
CN (1) CN101896190A (https=)
AR (1) AR069682A1 (https=)
AU (1) AU2008335840A1 (https=)
CA (1) CA2709027A1 (https=)
WO (1) WO2009075813A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148279A (zh) * 2014-10-21 2017-09-08 赛生制药有限公司 用免疫刺激剂治疗癌症

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
WO2013177102A2 (en) * 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system
WO2016133059A1 (ja) * 2015-02-16 2016-08-25 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
IT201900016310A1 (it) * 2019-09-13 2021-03-13 Luigina Romani Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTONI RIBAS ET AL.,: "Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206", 《JOURNAL OF CLINICAL ONCOLOGY》 *
张久聪 等: "胸腺肽α1的作用机制和临床应用", 《细胞与分子免疫学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148279A (zh) * 2014-10-21 2017-09-08 赛生制药有限公司 用免疫刺激剂治疗癌症

Also Published As

Publication number Publication date
US20100330093A1 (en) 2010-12-30
AR069682A1 (es) 2010-02-10
WO2009075813A1 (en) 2009-06-18
EP2240195A1 (en) 2010-10-20
EP2240195A4 (en) 2011-12-21
CA2709027A1 (en) 2009-06-18
JP2011506436A (ja) 2011-03-03
AU2008335840A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
CN101896190A (zh) 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤
ZA200309060B (en) Combination therapy using anit-angiogenic agents and TNFalpha.
WO2009079338A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
CN111836647A (zh) Cd47阻断疗法和cd38抗体的组合
JP6591665B2 (ja) Ｔ−ｄｍ１難治性がん患者のｓｙｄ９８５処置
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
US10011636B2 (en) Inhibitors of metastasis
RU2639445C2 (ru) Лекарственное средство, содержащее рекомбинантные лектины омелы, для лечения злокачественной меланомы
US20230173049A1 (en) Fusion proteins and methods of use thereof
AU2019235627B2 (en) Improvements in CD47 blockade therapy by EGFR antibody
CN111617235A (zh) Il-12在术后抗肿瘤方面的应用
JP2022551672A (ja) 乳癌治療法
WO2016071431A9 (en) A combination for cancer therapy
US20240207199A1 (en) Fluorocarbon compositions and methods for enhancing immunotherapy
US20210386736A1 (en) Combination therapy for treating cancer
US20200121720A1 (en) Nk-92 cells and il-15 agonist combination therapy
US20100267637A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
US12102649B2 (en) Methods and compositions for treating endometriosis
Soori et al. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study
EP0692259A2 (en) Use of HCG-specific antibody for the treatment of brain neoplasms
WO2025261276A1 (zh) 含抗cd20抗体药物偶联物的药物组合及其治疗非霍奇金淋巴瘤的用途
WO2019110688A1 (en) A composition comprising degarelix for use in the treatment of breast cancer
HK1221159B (en) Mareks inhibitor peptides for inhibiting metastasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101124